FIASP

This brand name is authorized in United States. It is also authorized in Albania, Australia, Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Ireland, Japan, Lithuania, Netherlands, Poland, Romania, South Africa, Spain, Turkey, UK.

Active ingredients

The drug FIASP contains one active pharmaceutical ingredient (API):

1	Insulin aspart UNII D933668QVX - INSULIN ASPART
	The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection.
	Read more about Insulin aspart

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10AB05	Insulin aspart	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10A Insulins and analogues → A10AB Insulins and analogues for injection, fast-acting
Discover more medicines within A10AB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AL	Fondi i Sigurimit të Detyrueshëm të Kujdesit Shëndetësor	446/93a
AU	Pharmaceutical Benefits Scheme	11705C, 11706D
BR	Câmara de Regulação do Mercado de Medicamentos	526618120010007, 526618120010107, 526619110007607, 526619110007707, 526619110007807
CA	Health Products and Food Branch	02460408, 02460416, 02460424
EE	Ravimiamet	1736906, 1736917, 1736928, 1736940, 1736951, 1736962, 1736973, 1736984, 1829965, 1829976
ES	Centro de información online de medicamentos de la AEMPS	1161160001, 1161160007, 1161160010, 1161160012
FI	Lääkealan turvallisuus- ja kehittämiskeskus	066518, 178981, 435387, 472559
FR	Base de données publique des médicaments	60810891, 64366900, 65741417, 68772407
GB	Medicines & Healthcare Products Regulatory Agency	340431, 340433, 340435
IE	Health Products Regulatory Authority	43903, 43911, 43918, 43919
JP	医薬品医療機器総合機構	2492415A5026, 2492415A6022, 2492415G7021
LT	Valstybinė vaistų kontrolės tarnyba	1081965, 1081966, 1081967, 1081968, 1081969, 1081970, 1081972, 1081973, 1081974, 1081975, 1081976, 1090529, 1090530
NL	Z-Index G-Standaard, PRK	121355, 121495, 53880, 53902
PL	Rejestru Produktów Leczniczych	100380382
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63975001, W63975002, W63975003, W63975004, W63975005, W63975006, W63976001, W63976002, W63977001, W63977002, W63977003
TR	İlaç ve Tıbbi Cihaz Kurumu	8699676950256, 8699676950263, 8699676950270, 8699676950287, 8699676950294
US	FDA, National Drug Code	0169-3201, 0169-3204, 0169-3205
ZA	Health Products Regulatory Authority	51/21.1/0733